4.8 Article

Mapping global variation in dengue transmission intensity

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 12, 期 528, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aax4144

关键词

-

资金

  1. National Institute of General Medical Sciences MIDAS program [5U01GM110721]
  2. U.K. National Institute of Health Research [PR-OD-1017-20002]
  3. U.K. Medical Research Council (MRC) [MR/R015600/1]
  4. U.K. Department for International Development (DFID) under the MRC/DFID Concordat agreement
  5. Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA)
  6. U.S. CDC Southeastern Center of Excellence in Vector-borne Diseases (CDC) [U01CK000510]
  7. U.S. National Institute of General Medical Sciences [5U54GM08849]
  8. Bill and Melinda Gates Foundation [OPP1092240]
  9. MRC [MR/R015600/1] Funding Source: UKRI
  10. Bill and Melinda Gates Foundation [OPP1092240] Funding Source: Bill and Melinda Gates Foundation

向作者/读者索取更多资源

Intervention planning for dengue requires reliable estimates of dengue transmission intensity. However, current maps of dengue risk provide estimates of disease burden or the boundaries of endemicity rather than transmission intensity. We therefore developed a global high-resolution map of dengue transmission intensity by fitting environmentally driven geospatial models to geolocated force of infection estimates derived from cross-sectional serological surveys and routine case surveillance data. We assessed the impact of interventions on dengue transmission and disease using Wolbachia-infected mosquitoes and the Sanofi-Pasteur vaccine as specific examples. We predicted high transmission intensity in all continents straddling the tropics, with hot spots in South America (Colombia, Venezuela, and Brazil), Africa (western and central African countries), and Southeast Asia (Thailand, Indonesia, and the Philippines). We estimated that 105 [95% confidence interval (CI), 95 to 114] million dengue infections occur each year with 51 (95% CI, 32 to 66) million febrile disease cases. Our analysis suggests that transmission-blocking interventions such as Wolbachia, even at intermediate efficacy (50% transmission reduction), might reduce global annual disease incidence by up to 90%. The Sanofi-Pasteur vaccine, targeting only seropositive recipients, might reduce global annual disease incidence by 20 to 30%, with the greatest impact in high-transmission settings. The transmission intensity map presented here, and made available for download, may help further assessment of the impact of dengue control interventions and prioritization of global public health efforts.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据